Clinical trials: Patients with Advanced Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003707
- Testing
- gemcitabine hydrochloride, tipifarnib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
This is a Phase 1a/1b, multicenter, open-label, first-in-human (FIH) study with MX006 treatment in patients with selected tumor types known to express B7-H3.
- Trial name
- NCT07807241
- Testing
- MX006
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 120 people
- Sponsor
- Myricx Pharma Limited
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Advanced Solid Tumor, Advanced Breast Cancer
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
- Trial name
- NCT06120283
- Testing
- BGB-43395, Fulvestrant, Letrozole
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 433 people
- Sponsor
- BeOne Medicines
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Unspecified Adult Solid Tumor, Protocol Specific
BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
Phase I trial to study the effectiveness of BMS-214662 plus trastuzumab in treating patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Trial name
- NCT00022529
- Testing
- BMS-214662, trastuzumab, pharmacological study
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
- Trial name
- NCT04111445
- Testing
- ADG116
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Adagene Inc
Solid Tumor, Gastric Cancer
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT04400383
- Testing
- AB011 Injection
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Patients will be enrolled in two stages: Dose-escalation stage: Approximately 15-30 patients will be enrolled. Dose-expansion stage: 6-12 patients will be enrolled.
- Trial name
- NCT03478995
- Testing
- GX-I7
- Where
- 3 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- Genexine, Inc.
Cancer
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies (including hepatocellular carcinoma and…
- Trial name
- NCT01546519
- Testing
- Vismodegib
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
BMS-184476 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-184476 in treating patients who have advanced solid…
- Trial name
- NCT00003705
- Testing
- BMS-184476
- Where
- 2 sites in United States
- Sponsor
- San Antonio Cancer Institute
Solid Tumors
A Study of ZG005 in Patients With Advanced Solid Tumors
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
- Trial name
- NCT06233292
- Testing
- ZG005 Powder for Injection
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed
Advanced Solid Cancers, Breast Cancer
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
This is a phase 1 study of investigational agent CFI-402257 in patients with advanced cancer. The purpose of this study is to see how safe and tolerable CFI-402257 is in cancer patients as well as the pharmacokinetics (PK).
- Trial name
- NCT02792465
- Testing
- CFI-402257, Fulvestrant
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
Neoplasms
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with…
- Trial name
- NCT07276373
- Testing
- Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Solid Tumor
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions.
- Trial name
- ONTRK (NCT03182257)
- Testing
- ONO-7579
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 1 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the safety of the combination of BMN 673 and carboplatin, and subsequently BMN 673 in combination with paclitaxel and carboplatin to determine…
- Trial name
- NCT02358200
- Testing
- BMN-673, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Pamela Munster
Sarcoma, Cervical Cancer
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
The present trial is an open, single-arm phase I clinical study aimed at assessing the safety, tolerability, viral distribution and shedding patterns, pharmacodynamics, immunogenicity, and antitumor efficacy of GC001 oncolytic…
- Conditions
- Sarcoma, Cervical Cancer, Colon Cancer, Lung Cancer
- Trial name
- NCT06508307
- Testing
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors
- Where
- China
- Volunteers
- 21 people
- Sponsor
- GONGCHU Biotechnology Co., Ltd
Advanced Solid Tumor
Study to Assess AFM24 in Advanced Solid Cancers
AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has…
- Trial name
- NCT04259450
- Testing
- 14 mg AFM24, 40 mg AFM24, 80 mg AFM24
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 85 people
- Sponsor
- Affimed GmbH
Advanced Solid Tumor
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
- Trial name
- NCT02189174
- Testing
- CLR457
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.